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Summary
We report a case of partial diazoxide responsiveness in a child with severe congenital hyperinsulinaemic hypoglycaemia 
(CHI) due to a homozygous ABCC8mutation.Atermbaby,withbirthweight3.8 kg,borntoconsanguineousparents
presentedonday1oflifewithhypoglycaemia.HypoglycaemiascreenconfirmedCHI.Diazoxidewascommencedonday
7duetoongoingelevatedglucoserequirements(15 mg/kg/min),butdespiteescalationtoamaximumdose(15 mg/kg/
day),intravenous(i.v.)glucoserequirementremainedhigh(13 mg/kg/min).Genetictestingdemonstratedahomozygous
ABCC8splicingmutation(c.2041-1G>C),consistentwithadiffuseformofCHI.Diazoxidetreatmentwasthereforestopped
and subcutaneous (s.c.) octreotide infusion commenced. Despite this, s.c. glucagon and i.v. glucose were required 
to prevent hypoglycaemia. A trial of sirolimus and near-total pancreatectomy were considered, however due to the 
significantmorbiditypotentiallyassociatedwiththese,afurthertrialofdiazoxidewascommencedat1.5 monthsof
age.Atadoseof10 mg/kg/dayofdiazoxideand40 µg/kg/dayofoctreotide,bothi.v.glucoseands.c.glucagonwere
stopped as normoglycaemia was achieved. CHI due to homozygous ABCC8mutationposesmanagementdifficultiesifthe
somatostatinanalogueoctreotideisinsufficienttopreventhypoglycaemia.Diazoxideunresponsivenessisoftenthought
to be a hallmark of recessively inherited ABCC8 mutations. This patient was initially thought to be non-responsive, but 
this case highlights that a further trial of diazoxide is warranted, where other available treatments are associated with 
significantriskofmorbidity.
-18-0120ID: 18-0120
Correspondence 
should be addressed 
to P Shah 
Email 
pratik.shah@gosh.nhs.uk
Learning points:
•• Homozygous ABCC8 mutations are commonly thought to cause diazoxide non-responsive hyperinsulinaemic 
hypoglycaemia.
•• This case highlights that partial diazoxide responsiveness in homozygous ABCC8 mutations may be present.
•• Trial of diazoxide treatment in combination with octreotide is warranted prior to considering alternative 
treatments,suchassirolimusornear-totalpancreatectomy,whichareassociatedwithmoresignificantside
effects.
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Background
Congenital hyperinsulinaemic hypoglycaemia (CHI) is the 
most common cause of persistent severe hypoglycaemia 
presenting in the neonatal period (1). The underlying 
cause of hyperinsulinism and the presence of diffuse or 
focal disease can be determined by genetic, radiological 
and histopathological investigations (2). Response 
to medical treatment can sometimes be predicted by 
genotype, particularly in those affected by diffuse disease 
caused by a homozygous mutation in the ABCC8 or 
KCNJ11 genes. These genes encode components of the 
voltage gated potassium channel of pancreatic beta 
cells (SUR1 and Kir6.2 respectively). Mutation results in 
unregulated release of insulin from the beta cells and 
subsequent hypoglycaemia (3).
Diazoxide acts directly via the SUR 1 subunit of the 
voltage gated potassium channel, reducing depolarisation 
and therefore preventing unregulated insulin release. 
When homozygous ABCC8 mutations are present, 
diazoxide is unable to act to prevent hypoglycaemia (4).
The clinical case of a neonate with CHI due to 
homozygous ABCC8 mutations is presented. In this 
case, initial non-response to diazoxide was seen, but a 
further trial in combination with octreotide appeared 
to be successful, suggesting a partial response. This was 
unexpected in the case of a patient with homozygous 
ABCC8 mutations, and allowed avoidance of alternative 
medical and surgical management of CHI which is 
associated with significant morbidity.
Case presentation
A term male infant (birth weight 3.8 kg, +0.52 SDS) was 
the first baby born to consanguineous parents, with a 
maternal history of gestational diabetes. He presented 
with hypoglycaemia on day 1 of life. A hypoglycaemia 
screen confirmed CHI (Table 1).
Diazoxide was commenced on day 7 due to ongoing 
elevated intravenous (i.v.) glucose requirements 
(15 mg/kg/min). Despite gradual escalation in diazoxide 
dose to 15 mg/kg/day, there was minimal response in 
glucose requirement (13 mg/kg/min). On day 25 he was 
transferred to a centre specialising in CHI management.
Investigation
On admission to the specialist centre, on day 25 of life, 
point-of-care test blood glucose was carried out hourly. 
Hypoglycaemia was defined as blood glucose (BG) 
<3.5 mmol/L. A centrally inserted venous catheter was 
placed to allow blood investigations and delivery of 
concentrated intravenous glucose.
Diazoxide treatment was discontinued due to 
the previously reported poor response, and to allow a 
controlled hypoglycaemia screen to be carried out. This 
confirmed CHI (Table 1).
Genetic testing demonstrated a homozygous ABCC8 
splicing mutation (c.2041-1G>C), consistent with diffuse 
form of CHI. Poor response to diazoxide was therefore 
anticipated. Both parents were shown to be heterozygous 
carriers of the mutation.
Treatment
Given the anticipated and previously reported poor 
response to diazoxide, a 10 µg/kg/day subcutaneous (s.c.) 
octreotide infusion was commenced on day 32. Diazoxide 
was subsequently restarted in addition on day 39, and was 
gradually increased to a maximum dose of 15 mg/kg/day 
by day 44. Furosemide and spironolactone were given to 
prevent fluid overload.
Ongoing hypoglycaemia was seen on hourly blood 
glucose profile and therefore octreotide was increased to a 
maximum dose of 30 µg/kg/day over a period of a further 
16  days. At 30 µg/kg/day octreotide and 15 mg/kg/day 
Table 1 Day 3 and day 31 hypoglycaemia screens: showing inappropriately elevated insulin concentration in the context of 
hypoglycaemia,withoutmobilisationofnon-esterifiedfattyacidsandbeta-hydroxybutyrateproduction.Consistentwithdiagnosis
of hyperinsulinaemic hypoglycaemia.
Biochemistry Day 3: results Day 31: results Reference range
Glucose(mmol/L) 2 2.1 2.6–5.5
Insulin(mU/L) 21 8.8 <5 when hypoglycaemic
Non-esterifiedfattyacid(mmol/L) 0.24 0.24
Beta-hydroxybutyrate(mmol/L) <0.05 <0.05
Lactate(mmol/L) 1.1 <2
Ammonia (μmol/L) <50 18 <50
Cortisol(nmol/L) 263 364
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diazoxide treatment, i.v. glucose requirement reduced to 
1.7 mg/kg/min, i.v. glucagon reduced to 1 µg/kg/h and 
the baby received high-energy milk equivalent to 8.4 mg/
kg/min of carbohydrate as a continuous nasogastric (NG) 
feed. Given that poor response to diazoxide had been 
anticipated and no clear response attributable to diazoxide 
alone had been seen during this second trial of diazoxide, 
the drug was discontinued again and the octreotide dose 
further increased to 40 µg/kg/day.
During this period episodes of hypoglycaemia 
recurred on hourly glucose profile, requiring an increase 
in i.v. glucose delivery (from 1.7 to 3.5 mg/kg/min) and 
s.c. glucagon (from 1 to 5 µg/kg/h).
Further management options were considered, 
including use of sirolimus (mTOR inhibitor) or near-
total pancreatectomy. Neither of these options were 
thought to be without significant risk of morbidity. The 
baby had postnatally acquired CMV infection. Use of 
sirolimus in a neonate in this scenario has not previously 
been documented, and would require close monitoring 
of the viral load and potential treatment with anti-viral 
medication. The possible complications of near-total 
pancreatectomy include ongoing CHI, diabetes mellitus, 
pancreatic exocrine insufficiency and damage to the 
common bile duct.
To avoid both of these treatments, a further trial 
of diazoxide with furosemide and spironolactone was 
commenced on day 66. On this occasion, at a dose of 
10 mg/kg/day of diazoxide, both i.v. glucose and s.c. 
glucagon were stopped as normoglycaemia was achieved 
(Fig. 1).
From day 72, octreotide was given by 6 hourly s.c. 
injection at 40 µg/kg/day. Milk feeds via gastrostomy 
provided the equivalent of 11.9 mg/kg/min of 
carbohydrate.
Outcome and follow-up
The baby was discharged at 3.5  months of age treated 
with 10 mg/kg/day of oral diazoxide and 40 µg/kg/day 
of octreotide given by 6 hourly s.c. injection. A feeding 
regimen consisting of a standard infant formula 
supplemented with additional carbohydrate of 12% 
concentration was well tolerated. Three hourly bolus 
feeds were given during the daytime and an overnight 
continuous feed to total 150 mL/kg/day. Blood glucose 
was stable on this regimen and fasting ability on 6-h 
controlled fast was demonstrated.
Regular reassessment was carried out. At the age of 
13  months, the child remained treated with octreotide 
(38 µg/kg/day) and diazoxide (9.5 mg/kg/day) and on 
3 hourly daytime feeds (solids and cow’s milk) and a 
continuous overnight feed via gastrostomy. A controlled 
fast demonstrated hypoglycaemia at 4 h, indicating 
ongoing severe CHI.
At the age of 23 months, the child was treated with 
octreotide (38 µg/kg/day) and diazoxide (9.5 mg/kg/day) 
on 3-hourly daytime feeds (solids and cow’s milk) and a 
Figure 1
I.v. glucose delivery (mg/kg/min) and 
subcutaneousglucagondose(µg/kg/h)oneach
day of age during CHI Centre admission. 
Diazoxide treatment had been commenced in the 
local hospital but was discontinued on admission 
to allow a controlled hypoglycaemia screen to be 
carried out.
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continuous overnight feed via gastrostomy. No episodes 
of hypoglycaemia occurred on hourly blood glucose 
profile over 24 h. Hypoglycaemia again developed after 
4 h of controlled fast.
Lanreotide (a long acting somatostatin analogue) was 
commenced at 23 months of age at a dose of 30 mg by deep 
s.c. injection every 4 weeks. Octreotide was subsequently 
weaned and stopped by 25.5 months of age. The transition 
from lanreotide to octreotide was not made at an earlier 
stage due to barriers to hospital attendance for adequate 
monitoring of the transition. Further assessment at 
25.5 months of age showed adequate growth (Table 2). A 
plan for repeat assessment with blood glucose profile and 
controlled fast is planned. If stability in glycaemic control 
is demonstrated, the diazoxide dose will be weaned with 
careful monitoring of response.
Discussion
CHI patients with recessive inactivating mutations in 
ABCC8 or KCNJ11 genes have defective production, 
turnover or trafficking of KATP channels resulting in 
constant depolarisation of the beta cell membrane 
and therefore persistent insulin secretion (5, 6). The 
mechanism of action of diazoxide is via the SUR1 subunit 
of the KATP channel, reducing depolarisation. In patients 
with a homozygous recessive ABCC8 gene mutation, 
diazoxide therefore does not usually prevent insulin 
secretion.
Diazoxide unresponsiveness is often thought to be 
a hallmark of recessively inherited ABCC8 mutations. 
A large review of 417 cases of CHI carried out at The 
Children’s Hospital of Philadelphia found that no patient 
with a homozygous ABCC8 mutation was responsive to 
diazoxide (7). Dekel et al. (8) report a patient carrying a 
biallelic mutation in the ABCC8 gene that had diazoxide 
responsive CHI. This child had a compound heterozygosity 
for two mutations in the ABCC8 gene, (c.3992-9G->A) and 
(p.Phe1388del). The authors postulated that although one 
of these mutations is known to cause severe non-diazoxide 
responsive disease (with in vitro studies demonstrating no 
channel activity by the mutant protein), the compound 
heterozygous nature in this case may have resulted in a 
milder phenotype as the maternally inherited allele has 
been associated with CHI of variable severity.
Arya et al. (9) also reported a case of a child with a 
compound heterozygous mutation in the ABCC8 gene 
who was responsive to diazoxide. A missense mutation 
in p.Arg526Cys and a frameshift mutation c.1879delC 
(p.His627fs*20) was identified. Response to diazoxide was 
also confirmed in this case in functional studies of the 
mutant KATP channel in a hamster model.
Diazoxide responsiveness in a child with a 
homozygous ABCC8 gene mutation has not been reported 
in the literature prior to this case. We describe a patient 
with CHI due to a homozygous ABCC8 splicing mutation 
(c.2041-1G>C) who did appear to show partial response 
to diazoxide, sufficient to avoid additional treatment with 
subtotal pancreatectomy or an mTOR inhibitor.
Marked clinical heterogeneity has previously been 
reported in siblings with identical mutations in ABCC8 
gene (10). Although the mechanism for this variability 
is unknown, postulated explanations include effect of 
modifying genes, and epigenetic and environmental 
factors. Differences in the splicing factor machinery may 
influence the phenotypic expression of the splice site 
mutation, resulting in individuals expressing variable 
proportions of the functioning transcript.
Our patient has a canonical splice site which is likely 
to result in aberrant splicing and nonsense mediated 
decay of the formed protein. In this case, the splice site 
is not predicted to be abolished, but reduced in strength. 
The occurrence of some normal splicing would result in 
some KATP channels which do reach the cell surface. These 
would be normal in structure and function and therefore 
able to respond to diazoxide. This may explain a partial 
response to diazoxide in this case.
It could be argued that CHI cases tend to become 
milder overtime and therefore a reduction in severity 
of disease is responsible for the apparent response to 
diazoxide in this patient. A number of individual cases of 
spontaneous resolution have been reported (11). A review 
of 21 patients consecutively presenting with CHI due to 
Table 2 Clinical, biochemical and therapeutic responses of 
the patient at most recent assessment.
Latest clinical and biochemical assessment
Age 25 months
Current weight 11.15 kg(−1.3 SDS)
Current height 79.8 cm(−1.9 SDS)
Current height velocity 7.19 cm/year(−1.5 SDS)
Current medications Lanreotide30 mg(4 weekly/s.c.)
Diazoxide8 mg/kg/day(TDS/oral)
Spironolactone1.6 mg/kg/day 
(BD/oral)
Furosemide1.6 mg/kg/day(BD/oral)
Current feeding plan 
 
 
 
 
Daytime:fedevery4 hwith3meals
(solids)andsnacksand100–200 mL
cow’s milk with added vitajoule (total 
10% carbohydrate)
Overnight:Nutrini35 mL/hfor11 h
via gastrostomy
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KATP channel gene mutations was carried out at one CHI 
centre (12). The authors report frequent resolution in CHI 
that was not predicted by the gene mutation. Complete 
resolution was seen in some patients with recessively 
inherited CHI with homozygous and compound 
heterozygous mutations. Reduction in severity of CHI, as 
indicated by reduced diazoxide dose and discontinuation 
of somatostatin receptor agonists, was seen in all patients. 
Regular reassessment of disease severity is therefore 
required to identify disease resolution and avoid the need 
for escalation of treatment.
In our reported case, it is not possible to accurately 
identify the relative contribution of octreotide, diazoxide 
and the natural course of reducing severity of disease 
on this baby’s blood glucose stabilisation. However, 
the patient had evidence of ongoing severe CHI at the 
last clinical reassessment at 23  months of age, with 
significantly shortened fasting time than would be 
expected for their age. Therefore resolution of CHI has 
not occurred, but similarly full responsiveness to medical 
treatment has not been seen.
The patient’s trial with diazoxide in early life was 
deemed to be unsuccessful, with only a minor fall in i.v. 
glucose infusion rate. It is possible that the maximum 
response was only apparent in combination with 
octreotide treatment, when glucose infusion rates had 
already been reduced, or when there may have already 
been some reduction in disease severity beyond the first 
month of life.
At present it is not felt appropriate to discontinue trial 
of diazoxide again, given the very short fasting time of the 
child. However this will be considered in future if fasting 
time improves. It is important to minimise treatment 
burden for patients and their families.
Conclusion
This case demonstrates that partial diazoxide 
responsiveness, in combination with octreotide treatment, 
may be seen in children with homozygous ABCC8 gene 
mutations. It is essential to assess response to diazoxide 
carefully, even in patients in whom non-response would 
be predicted, as this has the potential to avoid the use of 
treatments with more significant complications and side 
effects.
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